Epilepsy and Seizure Medication
  Novartis Pharma US

 





MONOTHERAPY is a realistic goal - See results from a study showing that more patients achieved seizure control with their first antiepileptic drug monotherapy than with their second monotherapy. Go

Novartis Medicare Resource Center

Patient Assistance Program - visit www.pap.novartis.com

Safety and Tolerability

Safety and Tolerability

The goal is control with favorable safety and tolerability

TRILEPTAL offers a favorable safety profile

Few drug-drug interactions,* and no routine blood monitoring required
Linear pharmacokinetics with no autoinduction
Not associated with cosmetic side effects such as coarsening of facial features or unusual hair growth
Weight neutral (no significant weight loss or gain compared with placebo)1

See safety data

Man Spinning Basketball
Safety
Tolerability

TRILEPTAL is well tolerated

Well tolerated monotherapy with low rates of discontinuation due to behavioral, psychiatric, or cognitive side effects in controlled clinical trials See tolerability data
Well tolerated in a pediatric population as young as 2 years See efficacy data
—  Also well tolerated in a pediatric monotherapy trial (patients aged 4 to 17 years)
See efficacy data

*A decrease in the dose of phenytoin may be required when TRILEPTAL is added on at dosages >1200 mg/day. TRILEPTAL may also reduce the effectiveness of certain oral contraceptives.

References:
1. Pedersen B, D'Souza J. Oxcarbazepine (Trileptal®) therapy results in no clinically significant changes in weight. Poster presented at: 5th European Congress of Epilepsy; October 6-10, 2002; Madrid, Spain.



E-mail this page  | Print this page




TRILEPTAL Home  |  Professionals Main Page  |  Efficacy
Safety and Tolerability  |  Dosing  |  Resource Center
Important Safety Information  |  Prescribing Information

Site Guide  |  Contact Us  |  Sitemap

Novartis Pharma US Use of website is governed by the Terms of Use and Privacy Statement .
Copyright ©2008 Novartis Pharmaceuticals Corporation. All rights reserved.